BridgeBio Pharma Inc annual gross profit for fiscal TTM was $666 million, an increase of 40.5% from $474 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $666M | $474M | $218M | $7M | $74M | $67M | $8M | $38M | — | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $229M | $184M | $139M | $114M | $107M | $114M | $4M | $2M | $2M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BBIO metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All BBIO financial statements → Interactive BBIO charts →
About TickerBase · Data methodology & sources · Privacy · Terms